Novartis ends PhIII peanut allergy trial for ligelizumab, in another blow for once-hopeful Xolair successor

Novartis has again culled a late-stage trial of a biologic that it once thought could succeed Xolair, its Genentech-partnered anti-inflammatory treatment for asthma and other indications.

The Swiss Big Pharma terminated a Phase III trial of ligelizumab in patients with peanut allergy, according to a Jan….
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks